Biropepimut-S

DB14816InvestigationalVaccines

Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity).

Mechanism: Pharmacologically active on Melanoma-associated antigen 3
Curator reviewed
Also known as: MAGE-A3 trojan peptide vaccine
Code names: GL-0817

Resolves to

Compound

UNII6XJF4EZC5ZCAS911338-45-9

Targets

P43357MAGEA3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Biropepimut-S, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account